Study Review – Guselkumab vs secukinumab for moderate-to-severe psoriasis (ECLIPSE)

This review is of the ECLIPSE study: Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis.
A total of over 1000 patients were included in the study from 142 centres and independent commentary is provided by Professor Rodney Sinclair, Professor of dermatology at the University of Melbourne and Director of Sinclair Dermatology.

Please login below to download this issue (PDF)